Lexatumumab ELISA Kit (GXEL00011)

Lexatumumab ELISA Kit

Assay Genie's Lexatumumab ELISA Kit (SKU: GXEL00011) provides researchers with a reliable quantitative ELISA for the quantitative measurement of Lexatumumab in Plasma, Serum. Offering a measurement range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml, the kit is optimised for precision and ease of use in the research laboratory.

Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL). It was developed by Genentech as a drug for the treatment of cancers. This drug has been investigating in various trials for treating cancers including chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. The efficacy and selectivity of drozitumab in rhabdomyosarcoma (RMS) has been evaluated in preclinical models. And results showed that drozitumab is effective, in vitro, against the majority of RMS cell lines that express caspase-8 and, in vivo, may provide long-term control of RMS. In preclinical glioblastoma models, drozitumab has been found to induce apoptosis and colony formation in several glioblastoma cell lines combined with BV6 (combination index<0.1). A study about triple-negative breast cancer reported that drozitumab could induce apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes. The previous study about the treatment of pancreatic ductal adenocarcinoma has revealed that drozitumab could selectively eliminate CSCs, resulting in tumor growth inhibition and even regression of pancreatic tumors.

Complete with standards, buffers and detection reagents, the Lexatumumab ELISA Kit streamlines assay set-up so you can focus on results. Choose the Lexatumumab ELISA Kit from Assay Genie for quality you can trust.